Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
Purity: ≥98%
Epothilone D (formerly known as KOS 862; KOS-862; desoxyepothilone B) is a potent microtubule stabilizing agent that has high anticancer activity. It is a naturally occurring polyketide that was separated from Sorangium cellulosum, a myxobacterium. When epothilone D binds to tubulin, it prevents microtubule disintegration, which in turn stops mitosis, cellular growth, and motility.
Targets |
Microtubule/Tubulin
|
|
---|---|---|
ln Vitro |
|
|
ln Vivo |
|
|
Animal Protocol |
Mice: Three groups of mice (n = 3) are given intraperitoneal (i.p.) injections of 3.7 mg/kg of dissolved Epothilone D (epoD) in 100% DMSO. The mice are then put to sleep using approved methods at intervals of 0.25 to 24 hours. In a different study, three groups of mice (n=3) are injected with 3 mg/kg of epoD in 100% DMSO, and four, six, and ten days later, they are put to death. Using LC-MS/MS procedures, the levels of epothilone D (epoD) in brain and blood samples are ascertained. For a duration of three months, groups (n=10–13) of three-month-old PS19 tau Tg mice or their three-month-old non-Tg littermates receive weekly intraperitoneal injections (i.p.) of vehicle (DMSO), 1 mg/kg epoD, or 3 mg/kg epothilone D (ep. Pets are weighed every week and watched for indications of unusual behavior or distress. Testing of the mice's motor and cognitive abilities occurs after the last dosage. Upon euthanasia, the optic nerve (ON) and brain are removed for immunohistochemical examination. An organ weight assessment and necropsy are also performed on a subset of mice from each group.
|
|
References |
|
Molecular Formula |
C27H41NO5S
|
---|---|
Molecular Weight |
491.6831
|
Exact Mass |
491.27
|
Elemental Analysis |
C, 65.95; H, 8.40; N, 2.85; O, 16.27; S, 6.52
|
CAS # |
189453-10-9
|
Related CAS # |
(16R)-Epothilone D
|
Appearance |
Solid powder
|
SMILES |
C[C@H]1CCC/C(=C\C[C@H](OC(=O)C[C@@H](C(C(=O)[C@@H]([C@H]1O)C)(C)C)O)/C(=C/C2=CSC(=N2)C)/C)/C
|
InChi Key |
XOZIUKBZLSUILX-GIQCAXHBSA-N
|
InChi Code |
InChI=1S/C27H41NO5S/c1-16-9-8-10-17(2)25(31)19(4)26(32)27(6,7)23(29)14-24(30)33-22(12-11-16)18(3)13-21-15-34-20(5)28-21/h11,13,15,17,19,22-23,25,29,31H,8-10,12,14H2,1-7H3/b16-11-,18-13+/t17-,19+,22-,23-,25-/m0/s1
|
Chemical Name |
(4S,7R,8S,9S,13Z,16S)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclohexadec-13-ene-2,6-dione
|
Synonyms |
KOS 862; (-)-Desoxyepothilone B; (-)-Epothilone D; KOS-862; 12,13-Deoxyepothilone B; KOS862; 12,13-Desoxyepothilone B; Desoxyepothilone B; Epo D; Epothilone D; NSC 703147.
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: ≥ 100 mg/mL (~203.4 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.08 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.08 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.0338 mL | 10.1692 mL | 20.3384 mL | |
5 mM | 0.4068 mL | 2.0338 mL | 4.0677 mL | |
10 mM | 0.2034 mL | 1.0169 mL | 2.0338 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT00337649 | Completed | Drug: Epothilone D Drug: Herceptin |
Breast Cancer | Hoffmann-La Roche | May 2004 | Phase 1 Phase 2 |
NCT00030173 | Completed | Drug: Epothilone D (KOS-862) |
Neoplasms | Bristol-Myers Squibb | October 2001 | Phase 1 |
NCT00077259 | Completed | Drug: epothilone D | Colorectal Cancer | Memorial Sloan Kettering Cancer Center |
October 2003 | Phase 2 |
NCT00081107 | Completed | Drug: epothilone D | Lung Cancer | Memorial Sloan Kettering Cancer Center |
December 2003 | Phase 2 |
NCT00104130 | Terminated | Drug: KOS-862 | Prostate Cancer | Bristol-Myers Squibb | December 2004 | Phase 2 |